Aethlon Medical (AEMD) Corporate presentation summary

Investment highlights

• Developing a novel, patented Hemopurifier® blood purification device targeting cancer and viral diseases.

• Early clinical trials show clearance of viruses and extracellular vesicles (EVs) in vitro and in patients.

• Two FDA Breakthrough Device designations for advanced cancer and life-threatening viruses.

• Oncology trial recruiting in Australia and being initiated in India.

• Broad patent portfolio with protection extending to 2044 if pending applications are granted.

Hemopurifier® technology and mechanism

• Proprietary, patented device designed to clear tumor-derived EVs and life-threatening viruses from blood.

• Utilizes a hollow-fiber plasma separator with affinity resin targeting mannosylated nanoparticles.

• Compatible with existing dialysis or CRRT infrastructure.

• Safely administered in 165 sessions across 39 patients.

• Demonstrated in vitro and in vivo removal of cancer-derived EVs and enveloped viruses.

Clinical and preclinical pipeline

• Oncology trial in Australia: 3 sites open, 3 patients enrolled, first patient treated safely.

• Protocol amendments to increase enrollment and shorten time to treatment/data.

• Pipeline includes solid tumors, viral infections (COVID-19, Ebola, HCV, HIV), and organ transplantation.

• Preclinical research on Long COVID using patient samples to assess EV removal.